Development

INSIGHTS ON DRUG DEVELOPMENT

Integrating Phase-Appropriate Quality Standards
Incorporating phase-specific quality standards ensures GMP compliance. Collaborating with an experienced CDMO addresses late-stage quality needs and efficiently manages development timelines.
Using DSC And MDSC To Study Material Interactions Of APIs And Excipients
Thermal analysis reveals how particle size and morphology influence material interactions and stability. Learn how DSC and MDSC techniques uncover compatibility issues and guide better excipient selection.
5 Trends Impacting CMOs In 2025
In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies.
Selecting A CDMO For Custom Activated PEGs
Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.

Cell Culture Media Filtration: Evaluating Cell Culture Performance
10/23/2025

Cell culture performance remained consistent across PES and PVDF filters, even under worst-case filtration conditions. Discover a practical framework for evaluating membrane impact on CHO cell growth.
Navigating The Analytical Complexity Of Oligonucleotide Therapeutics
9/13/2024

From identity and purity testing using chromatography and electrophoresis to PCR and microbial studies, explore advanced analytical solutions tailored for siRNA, miRNA, pDNA, and mRNA products.
Use Of Reconstructed Tissue And 3D Printed CT-Based Nasal Casts
7/3/2025

Reconstructed nasal epithelium and CT-based 3D nasal casts provide more predictive, physiologically relevant models for assessing nasal drug delivery, improving accuracy in formulation development.
Accelerating The Study Of Viral Infection And Therapeutics
8/7/2024

Explore the utilization of the Organ-Chips for investigating viral infections and expediting the development of new therapeutics.
Multifactorial Disease Models: De-Risking Topical Formulation Development
10/20/2025

Traditional drug models fail to predict performance in human skin. Advanced, multifactorial ex vivo disease models directly address inflammation and infection to de-risk formulation development.

PBPK Predictive Modeling Services

Early identification of potential absorption risks is critical for rapid and efficient drug development. Lonza's PBPK modeling services are designed to de-risk your drug development program.
Payload-Linker

Learn how high‑potency infrastructure, strong impurity control, and scalable payload‑linker capabilities help teams manage risk, maintain purity, and advance toward clinical‑stage ADC development.
ImageXpress Confocal HT.ai High-Content Imaging System

A scalable, high-throughput, high-content screening solution with 7-channel high-intensity laser light source and machine learning capabilities.
Transforming Tissue Research With Open Multiplexing

Cell DIVE Multiplex Imaging Solution

What if every scientist could map normal and diseased tissue by cell type, biomarker profile, and specific features?

Cell DIVE is a precise, open multiplexing solution that lets your research dictate the level of automation required, which antibodies to use, how to build your antibody panel, and more.
Guarantee A Successful Expansion With An Organoid Expansion Service

Explore an expansion service with experts that will work closely with you to customize your process and meet your unique needs by adjusting protocols, optimizing conditions, and providing personalized support.